ArticleJournal of tropical medicine2026
Deworming Coverage and Associated Factors Among Children Aged 12-59 Months in Sub-Saharan Africa: A Multilevel Poisson Regression Analysis Using Demographic and Health Survey Data, 2021-2024.
Article in Journal of tropical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Under the revised Demographic and Health Survey-8 (DHS-8) guidelines, deworming coverage is assessed only among children aged 12-59 months in accordance with World Health Organization recommendations. However, evidence for this age group in sub-Saharan Africa remains limited. Objective: To assess deworming coverage and associated factors among children aged 12-59 months in sub-Saharan Africa. Methods: A cross-sectional study was conducted using DHS data collected between 2021 and 2024 from 11 sub-Saharan African countries. A weighted sample of 96,830 children aged 12-59 months was included. Multilevel Poisson regression with a log link and robust variance estimation was used to estimate adjusted prevalence ratios (APRs) and 95% confidence intervals (CIs). Results: Overall, 47,426 of 96,830 children received deworming medication, giving coverage of 48.98% (95% CI: 48.67-49.30). Deworming coverage ranged from 32.0% in Burkina Faso to 66.0% in Kenya. Higher deworming prevalence was observed among children of mothers aged 25-34 years (APR = 1.04, 95% CI: 1.02-1.06) and 35-49 years (APR = 1.08, 95% CI: 1.06-1.10), those whose mothers had primary (APR = 1.19, 95% CI: 1.16-1.22), secondary (APR = 1.20, 95% CI: 1.18-1.26), or higher education (APR = 1.29, 95% CI: 1.20-1.34), and those who received vitamin A supplementation (APR = 2.75, 95% CI: 2.67-2.83). Children aged 36-59 months were also more likely to receive deworming medication (APR = 1.09, 95% CI: 1.08-1.11). Lower deworming prevalence was observed among children from households with ≥ 5 members (APR = 0.97, 95% CI: 0.95-0.98) and among those whose mothers reported distance to health facilities as a major problem (APR = 0.94, 95% CI: 0.92-0.96). Conclusion: Nearly half of eligible children received deworming medication in sub-Saharan Africa. Strengthening integrated maternal and child health services, improving women's education and decision-making capacity, and expanding access to services in underserved communities are crucial to increase deworming coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.